Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…